<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>European Society of Cardiology</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>CREB inhibitor protects rodents from PAH</title>
      <description>
        <![CDATA[Pulmonary arterial hypertension (PAH) is a condition that may lead to right heart dysfunction. Previous evidence has tied mitochondrial dynamics with the progression of PAH, but the mechanisms behind this are not well elucidated.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723905</guid>
      <pubDate>Fri, 05 Sep 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723905-creb-inhibitor-protects-rodents-from-pah</link>
    </item>
    <item>
      <title>CTRP7 predicts response to vasodilators in PAH</title>
      <description>
        <![CDATA[Pulmonary arterial hypertension (PAH) is a life-threatening disease; vasodilators may aid in managing this condition, but their impact on prognosis is still limited, potentially due to a lack of biomarkers to guide therapy. Japanese researchers have presented results of their efforts to discover potential molecular markers that may predict response to pulmonary vasodilators.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723882</guid>
      <pubDate>Thu, 04 Sep 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723882-ctrp7-predicts-response-to-vasodilators-in-pah</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Pulmonary-hypertension-heart-and-lungs.webp?t=1688391895" type="image/jpeg" medium="image" fileSize="153513">
        <media:title type="plain">Illustration of heart and lung vasculature in pulmonary hypertension vs. normal</media:title>
      </media:content>
    </item>
    <item>
      <title>EDEM2 emerges as therapeutic target in diabetic cardiomyopathy</title>
      <description>
        <![CDATA[The mechanisms behind diabetic cardiomyopathy (DCM) have been deeply studied but still not well-established within the scientific community. Mutations in cardiac junction proteins may result in heart failure and arrhythmia. ER degradation enhancing α-mannosidase like protein 2 (EDEM2) is involved in the degradation of misfolded N-glycosylated proteins, but its role in the heart is not clear and was investigated.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723876</guid>
      <pubDate>Thu, 04 Sep 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723876-edem2-emerges-as-therapeutic-target-in-diabetic-cardiomyopathy</link>
    </item>
    <item>
      <title>Kardium’s Globe PFA system gains FDA approval</title>
      <description>
        <![CDATA[Kardium Inc.’s Globe pulsed field system received U.S. FDA premarket approval, making it the fourth PFA system in the rapidly expanding market for cardiac ablation for atrial fibrillation. The system’s introducer sheath and mapping software also received clearance. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/723563</guid>
      <pubDate>Wed, 03 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723563-kardiums-globe-pfa-system-gains-fda-approval</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/image-single-shot-pvi-11june24.webp?t=1718145238" type="image/jpeg" medium="image" fileSize="126074">
        <media:title type="plain">Single Shot PVI</media:title>
        <media:description type="plain">Kardium Inc.’s Globe integrated mapping and pulsed field ablation system. Credit: Kardium Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>ESC 2025: From heart failure to hypertension, research advances</title>
      <description>
        <![CDATA[There have been numerous improvements in the treatment of cardiovascular disease since the European Society of Cardiology (ESC) first met in 1950, but unmet medical need remains and the science continues to advance, as delegates heard at the 75<sup>th</sup> annual meeting in Madrid, Spain, Aug. 29-Sept. 1.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723806</guid>
      <pubDate>Wed, 03 Sep 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723806-esc-2025-from-heart-failure-to-hypertension-research-advances</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Heart-scientific-overlay.webp?t=1729781889" type="image/jpeg" medium="image" fileSize="394419">
        <media:title type="plain">Heart scientific overlay</media:title>
      </media:content>
    </item>
    <item>
      <title>Impella pump use continues to reduce male mortality at 10 years</title>
      <description>
        <![CDATA[The Danish-German Cardiogenic Shock trial found that men implanted with Johnson & Johnson’s Impella CP after experiencing a heart attack with cardiogenic shock gain 600 days of life, on average, compared to usual care at 10 years. The study demonstrated no benefit for women.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723553</guid>
      <pubDate>Tue, 02 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723553-impella-pump-use-continues-to-reduce-male-mortality-at-10-years</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Impella-CP-2sept25.webp?t=1756851380" type="image/jpeg" medium="image" fileSize="25849">
        <media:title type="plain">Impella</media:title>
        <media:description type="plain">Johnson &amp;amp; Johnson’s Impella CP. Credit: J&amp;amp;J</media:description>
      </media:content>
    </item>
    <item>
      <title>Spectrawave’s Hypervue sees $50M in support</title>
      <description>
        <![CDATA[Spectrawave Inc. surfed to a $50 million haul in its series B fundraising round for its Hypervue intravascular imaging system. The company appears to have captured the attention of at least one strategic investor, as Johnson & Johnson Innovation-JJDC Inc. led the round.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712036</guid>
      <pubDate>Wed, 11 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712036-spectrawaves-hypervue-sees-50m-in-support</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/HyperVue_Feature_Updates_11sep24.webp?t=1726090525" type="image/jpeg" medium="image" fileSize="101461">
        <media:title type="plain">HyperVue Feature Updates</media:title>
        <media:description type="plain">Spectrawave Inc.’s Hypervue intravascular imaging system Credit: Spectrawave Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>PCSK9-targeted epigenetic editor therapy shows durable efficacy in mouse and NHP models</title>
      <description>
        <![CDATA[Researchers from Chroma Medicine Inc. presented preclinical data for the novel PCSK9-targeted epigenetic editor (PCSK9-EE) being developed as cardiovascular therapy for the reduction of low-density lipoprotein cholesterol.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712333</guid>
      <pubDate>Tue, 10 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712333-pcsk9-targeted-epigenetic-editor-therapy-shows-durable-efficacy-in-mouse-and-nhp-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NHGRI-Epigentics.webp?t=1667227835" type="image/png" medium="image" fileSize="1149238">
        <media:title type="plain">Epigenetics concept art.</media:title>
        <media:description type="plain">Credit: Darryl Leja, National Human Genome Research Institute, NIH
</media:description>
      </media:content>
    </item>
    <item>
      <title>Edwards’ Sapien TAVR devices superior to SAVR in women</title>
      <description>
        <![CDATA[In the first study to compare transcatheter aortic valve replacement or implantation to surgical aortic valve replacement exclusively in women, Edwards Lifescience Corp.’s Sapien 3 and Sapien 3 Ultra valves provided better outcomes. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/711962</guid>
      <pubDate>Fri, 06 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711962-edwards-sapien-tavr-devices-superior-to-savr-in-women</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2019/Edwards-SAPIEN3-12-6.webp?t=1575671551" type="image/png" medium="image" fileSize="130299">
        <media:title type="plain">Edwards-SAPIEN3-12-6.png</media:title>
        <media:description type="plain">Sapien 3 valve and delivery system. Credit: Edwards Lifesciences Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Effect of COR-1389 on cardiopulmonary function in pulmonary hypertension associated with right heart failure</title>
      <description>
        <![CDATA[Researchers from Corteria Pharmaceuticals SAS and Université Paris-Saclay recently presented the preclinical results on a long-acting corticotropin-releasing factor CRF2 receptor agonist, COR-1389.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712218</guid>
      <pubDate>Fri, 06 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712218-effect-of-cor-1389-on-cardiopulmonary-function-in-pulmonary-hypertension-associated-with-right-heart-failure</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Pulmonary-hypertension-heart-and-lungs.webp?t=1688391895" type="image/jpeg" medium="image" fileSize="153513">
        <media:title type="plain">Illustration of heart and lung vasculature in pulmonary hypertension vs. normal</media:title>
      </media:content>
    </item>
    <item>
      <title>ESC-ape velocity? Cytokinetics revs HCM case with aficamten </title>
      <description>
        <![CDATA[Cytokinetics Inc. CEO Robert Blum said his firm chalked “a watershed moment” during last weekend’s congress of European Society of Cardiology (ESC) in London, where further mid- and late-stage data were disclosed with the heart drug aficamten, a myosin inhibitor. South San Francisco-based Cytokinetics rolled out six presentations, including two late breakers, with four concurrent publications in medical journals.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712291</guid>
      <pubDate>Thu, 05 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712291-esc-ape-velocity-cytokinetics-revs-hcm-case-with-aficamten</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/heart-cross-section-valves.webp?t=1626905884" type="image/png" medium="image" fileSize="922624">
        <media:title type="plain">3D illustration of heart cross section</media:title>
      </media:content>
    </item>
    <item>
      <title>Abbott’s Mitraclip third trial: Triumph, TEERs and nuanced results</title>
      <description>
        <![CDATA[Hope for definitive resolution of the controversy about the superiority of transcatheter edge-to-edge repair of mitral valves over medical therapy in individuals with symptomatic heart failure and functional mitral regurgitation were dashed at the European Society of Cardiology meeting this weekend.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711943</guid>
      <pubDate>Wed, 04 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711943-abbotts-mitraclip-third-trial-triumph-teers-and-nuanced-results</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/1-13-Abbott-Mitraclip.webp?t=1593206168" type="image/png" medium="image" fileSize="828514">
        <media:title type="plain">Product image</media:title>
        <media:description type="plain">Mitraclip device. Credit: Abbott Laboratories</media:description>
      </media:content>
    </item>
    <item>
      <title>Therapeutic targeting of CHSY1 improves hyperplastic arterial remodeling in vivo</title>
      <description>
        <![CDATA[Researchers from the National University of Singapore and affiliated organizations presented data from a study that investigated the potential of targeting chondroitin sulfate (CS) synthesis as a therapeutic strategy for ameliorating hyperplastic arterial remodeling.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712130</guid>
      <pubDate>Wed, 04 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712130-therapeutic-targeting-of-chsy1-improves-hyperplastic-arterial-remodeling-in-vivo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/artery-cross-section-parts.webp?t=1715180484" type="image/jpeg" medium="image" fileSize="142511">
        <media:title type="plain">Medical illustration showing layers of a blood vessel</media:title>
      </media:content>
    </item>
    <item>
      <title>George’s triple-drug hypertension combo succeeds in phase III</title>
      <description>
        <![CDATA[George Medicines Ltd. has published positive data from two phase III studies showing GMRx2, a low-dose triple-drug combination treatment for hypertension, is superior to dual combinations of its components.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712192</guid>
      <pubDate>Tue, 03 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712192-georges-triple-drug-hypertension-combo-succeeds-in-phase-iii</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Blood-pressure-gauge-ECG-and-medication.webp?t=1715181324" type="image/jpeg" medium="image" fileSize="175581">
        <media:title type="plain">Blood pressure gauge, ECG and medication</media:title>
      </media:content>
    </item>
    <item>
      <title>KUS-121 shows therapeutic potential in models of atherosclerotic disease</title>
      <description>
        <![CDATA[The valosin-containing protein (VCP) modulator KUS-121 from Kyoto University is in phase II development as an intravitreal treatment for nonarteritic central retinal artery occlusion, but its efficacy in atherosclerosis is unknown.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712092</guid>
      <pubDate>Tue, 03 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712092-kus-121-shows-therapeutic-potential-in-models-of-atherosclerotic-disease</link>
    </item>
    <item>
      <title>hERG channel agonists show promise for treating long QT syndrome type 8</title>
      <description>
        <![CDATA[Repolarization abbreviation with the antiarrhythmic drug mexiletine has been found to normalize the QTc interval and reduce the rate of events in long QT syndrome type 3 (LQT3), but it is only partially efficacious in other malignant forms, including LQT2 and LQT8. There are compounds that have not been tested, such as hERG channel agonists, which are capable of shortening repolarization. The potent hERG agonist ICA-105574 was thus tested in a clinically relevant porcine model of LQT8.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712090</guid>
      <pubDate>Tue, 03 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712090-herg-channel-agonists-show-promise-for-treating-long-qt-syndrome-type-8</link>
    </item>
    <item>
      <title>Ghrelin receptor agonist improves cardiac function in preclinical heart failure</title>
      <description>
        <![CDATA[At the recent European Society of Cardiology meeting, Anacardio AB and Helsinn Healthcare SA presented data on their oral small-molecule ghrelin receptor agonist and first-in-class calcium sensitizing inotrope, AC-01, in preclinical models of heart failure.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712085</guid>
      <pubDate>Tue, 03 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712085-ghrelin-receptor-agonist-improves-cardiac-function-in-preclinical-heart-failure</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardio-heart-attack.webp?t=1595367448" type="image/png" medium="image" fileSize="363148">
        <media:title type="plain">Heart illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Keros Therapeutics’ RKER-012 ameliorates cardiomyopathy in preclinical PAH</title>
      <description>
        <![CDATA[Keros Therapeutics Inc. has presented preclinical data on the activin receptor type IIB ligand trap RKER-012 (a research version of KER-012 [cibotercept]) in a preclinical pulmonary arterial hypertension model.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712068</guid>
      <pubDate>Mon, 02 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712068-keros-therapeutics-rker-012-ameliorates-cardiomyopathy-in-preclinical-pah</link>
    </item>
    <item>
      <title>Study boosts potential of smartphones to screen for atrial fibrillation</title>
      <description>
        <![CDATA[Medical science has been experimenting with smart devices for several years to determine whether these products can detect circulatory system diseases, and a study presented at the 2022 meeting of the European Society of Cardiology (ESC 2022) seems to strongly suggest that the answer is a resounding yes. The eBRAVE-AF study of more than 5,500 enrollees of middle age or older demonstrated the ability of a smartphone camera and a downloadable app to at beat conventional screening for atrial fibrillation (AF), a finding that could save lives and boost the prospects of device makers in the digital health space.]]>
      </description>
      <guid>http://www.bioworld.com/articles/522042</guid>
      <pubDate>Tue, 30 Aug 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/522042-study-boosts-potential-of-smartphones-to-screen-for-atrial-fibrillation</link>
    </item>
    <item>
      <title>Conference data for Aug. 30, 2022: ESC</title>
      <description>
        <![CDATA[New and updated preclinical and clinical data presented by biopharma firms at the European Society of Cardiology, including: Amarin, Amgen, Astrazeneca, BMS, Daiichi, Tranquis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/522019</guid>
      <pubDate>Tue, 30 Aug 2022 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/522019-conference-data-for-aug-30-2022-esc</link>
    </item>
    <item>
      <title>Factor XIa inhibitors from BMS/Janssen, Bayer show promise in stroke studies, advance to phase III</title>
      <description>
        <![CDATA[Factor XIa inhibitors milvexian and asundexian, hailed as the next-generation class of anticoagulants, earned mixed reviews on phase II data presented during the European Society of Cardiology Congress 2022. However, developers Bristol Myers Squibb Co./Janssen Pharmaceutical Co. and Bayer AG, respectively, are moving into late-stage testing, citing clear mechanisms of action that put the FXIa drugs at least on par with approved factor Xa drugs in terms of efficacy while offering potentially better safety profiles that could give physicians an option for patients with stroke or atrial fibrillation who are currently undertreated with anticoagulants due to bleeding risks.]]>
      </description>
      <guid>http://www.bioworld.com/articles/522021</guid>
      <pubDate>Mon, 29 Aug 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/522021-factor-xia-inhibitors-from-bms-janssen-bayer-show-promise-in-stroke-studies-advance-to-phase-iii</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Hematologic/Blood-clot.webp?t=1745258777" type="image/jpeg" medium="image" fileSize="221301">
        <media:title type="plain">Blood clot blocking a blood vessel</media:title>
      </media:content>
    </item>
    <item>
      <title>Endotronix reports early data for heart failure sensor</title>
      <description>
        <![CDATA[Endotronix Inc. reported positive data from the SIRONA 2 clinical trial evaluating safety and efficacy of its Cordella pulmonary artery pressure sensor system in New York Heart Association (NYHA) class III heart failure (HF) patients. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/519130</guid>
      <pubDate>Tue, 24 May 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/519130-endotronix-reports-early-data-for-heart-failure-sensor</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/05-24-Endotronix-Cordella-Reader.webp?t=1653429524" type="image/png" medium="image" fileSize="696045">
        <media:title type="plain">Patient holding Cordella reader over heart</media:title>
        <media:description type="plain">Endotronix's pulmonary artery pressure sensor and reader for heart failure monitoring.</media:description>
      </media:content>
    </item>
    <item>
      <title>Abbott’s Amulet gives Watchman a run for its money in head-to-head trial</title>
      <description>
        <![CDATA[The race is on. After six years as the only FDA approved devices for left atrial appendage closure, Boston Scientific Corp.&rsquo;s Watchman products face a challenger, Abbott Laboratories&rsquo; Amplatzer Amulet. With the Amulet&rsquo;s FDA approval in mid-August and positive results in a head-to-head trial presented at the 2021 European Society of Cardiology Congress on Tuesday, the Watchman has reason to look over its shoulder at a competitor that could change the game entirely. The trial results were published simultaneously in <em>Circulation</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/510951</guid>
      <pubDate>Tue, 31 Aug 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/510951-abbotts-amulet-gives-watchman-a-run-for-its-money-in-head-to-head-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/2-3-abbott-amplatzer-amulet.webp?t=1580770040" type="image/png" medium="image" fileSize="742580">
        <media:title type="plain">2-3-abbott-amplatzer-amulet.png</media:title>
        <media:description type="plain">Amplatzer Amulet device. Credit: Abbott Laboratories </media:description>
      </media:content>
    </item>
    <item>
      <title>STOP-AF First shows cryoablation puts the brakes on treatment-naïve atrial fibrillation</title>
      <description>
        <![CDATA[Cryoablation for paroxysmal atrial fibrillation (PAF) is not the standard of care, but a recent study may change at least some clinicians&rsquo; thinking on that score. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/497275</guid>
      <pubDate>Tue, 01 Sep 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/497275-stop-af-first-shows-cryoablation-puts-the-brakes-on-treatment-na%C3%AFve-atrial-fibrillation</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardio-heart-attack.webp?t=1595367448" type="image/png" medium="image" fileSize="363148">
        <media:title type="plain">Heart illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Conference data for Aug. 31, 2020: European Society of Cardiology</title>
      <description>
        <![CDATA[New and updated preclinical and clinical data presented by biopharma firms at the European Society of Cardiology Congress 2020, including: Akcea, Amarin, Amgen, Arrowhead, Astrazeneca, Boehringer, Innovent, Lilly, Myokardia, Novartis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/497197</guid>
      <pubDate>Mon, 31 Aug 2020 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/497197-conference-data-for-aug-31-2020-european-society-of-cardiology</link>
    </item>
  </channel>
</rss>
